BH3 Profiling Mitochondrial Permeabilization Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biomarkers for cancer therapy are insufficient in predicting patient response to targeted therapies, and resistance to these drugs often emerges, making it unclear which treatment is best to administer after resistance emergence.
Innovation Solution
A method involving dynamic BH3 profiling, where a test cell population is exposed to a BH3 domain peptide to measure mitochondrial outer membrane permeabilization, indicating sensitivity to therapeutic agents, allowing for the identification of drugs that move cancer cells closer to the apoptotic threshold, thereby predicting response to chemotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional biomarkers are used for cancer therapy prediction, then the therapy can be directed to patients, but the biomarkers are insufficient and cannot accurately predict response to targeted therapies
Solution Approach 1:
The invention changes the measurement parameter from traditional genetic biomarkers to mitochondrial membrane potential and permeabilization parameters. By measuring the mitochondrial membrane potential (ΔΨm) and outer membrane permeabilization in response to BH3 peptides, the method achieves more accurate prediction of therapeutic response that adapts to various cancer types and resistance mechanisms
Solution Approach 2:
The invention introduces BH3 domain peptides as intermediary molecules to probe mitochondrial status. These peptides act as mediators that bind to BCL-2 family proteins and induce mitochondrial outer membrane permeabilization, providing an indirect but accurate readout of cellular sensitivity to therapy that overcomes the limitations of direct genetic biomarker assessment
2Productivity
If targeted therapies are administered based on limited biomarkers, then treatment can be initiated, but resistance frequently emerges making it unclear what treatment is best
Solution Approach 1:
The invention performs preliminary assessment of mitochondrial priming status before initiating targeted therapy. By measuring baseline mitochondrial membrane potential and testing response to BH3 peptides in advance, the method predicts which patients will respond to specific therapies and identifies potential resistance mechanisms beforehand, enabling more reliable long-term treatment outcomes
Solution Approach 2:
The invention creates a feedback loop where BH3 profiling results inform treatment selection and monitoring. The mitochondrial response data provides continuous feedback on cellular sensitivity status, allowing clinicians to adjust therapy regimens before resistance fully develops and to select alternative treatments when resistance emerges
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively predicts sensitivity to chemotherapeutic agents and identifies optimal treatments by measuring changes in mitochondrial priming, distinguishing between responsive and resistant cells, and has been shown to accurately predict clinical responses in various cancer types.
Implementation Method 1
measuring the amount of BH3 domain peptide induced mitochondrial outer membrane permeabilization
Implementation Method 2
contacting the permeabilized cell with a potentiometric dye. Potentiometric dyes include for example JC-1 or dihydrorhodamine 123
Data Source
AI summary
The present invention provides methods of predicting cell sensitivity or resistance to a therapeutic agent.